Mode
Text Size
Log in / Sign up

Measles

Part of Human Metapneumovirus Infection

19 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Measles

29 trials tracked for Measles: 24 in phase 3 or 4 and 10 with published results. The most-cited published study has 38 citations.

29Trials tracked
24Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 3 Phase 3 21 Phase 2 5
  1. Phase 3 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed · 38 cited
  2. Phase 3 Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Completed · 30 cited
  3. Phase 3 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed · 19 cited
  4. Phase 3 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Completed · 18 cited
  5. Phase 3 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed · 14 cited
  6. Phase 3 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) Completed · 13 cited
Show 23 more trials
  1. Phase 3 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed · 10 cited
  2. Phase 3 ProQuad® Intramuscular vs Subcutaneous Completed · 10 cited
  3. Phase 3 Safety Study of ProQuad® rHA in Infants (V221-037) Completed · 9 cited
  4. Phase 4 Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age Completed · 3 cited
  5. Phase 4 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Completed
  6. Phase 4 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed
  7. Phase 3 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed
  8. Phase 3 Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers Completed
  9. Phase 3 Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age Completed
  10. Phase 3 Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines Completed
  11. Phase 3 V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019) Completed
  12. Phase 3 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) Completed
  13. Phase 3 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers Completed
  14. Phase 3 A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Completed
  15. Phase 3 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed
  16. Phase 3 A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) Completed
  17. Phase 3 Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) Completed
  18. Phase 3 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed
  19. Phase 2 A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age Completed
  20. Phase 2 ProQuad Dose Selection Study (V221-011)(COMPLETED) Completed
  21. Phase 2 Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age Completed
  22. Phase 2 Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds Completed
  23. Phase 2 Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age Completed

Showing the 29 most-cited and recently-updated of 29 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about Measles

What public health response was used for measles among Afghan evacuees in the US?

Public health officials in the US organized a mass vaccination campaign specifically for Afghan evacuees after measles cases were identified within that group.

Full answer →
Did measles cases increase in Galmudug State, Somalia between 2023 and 2024?

Yes, measles cases increased in Galmudug State, Somalia, rising from an incidence of 4.9 per 10,000 people in 2023 to 8.1 per 10,000 in 2024.

Full answer →

All Measles Articles